<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03337152</url>
  </required_header>
  <id_info>
    <org_study_id>856370-2</org_study_id>
    <nct_id>NCT03337152</nct_id>
  </id_info>
  <brief_title>Assessing a Risk Model for G6PD Deficiency</brief_title>
  <official_title>Developing a Methodology to Assess 8-aminoquinoline Associated Haemolytic Risk in Females Heterozygous for G6PD in Endemic Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mahidol Oxford Tropical Medicine Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study designed to develop and inform an individual risk of hemolysis model based&#xD;
      on individual red blood cell G6PD levels. Volunteers who are eligible to treatment with&#xD;
      primaquine as per national guidelines and with confirmed normal G6PD levels as per the&#xD;
      fluorescent spot test will be exposed to treatment regimens of either primaquine alone for 14&#xD;
      days or 3 day chloroquine with concomitant primaquine for 14 days. The volunteers will be&#xD;
      followed intensively during treatment and for 14 days after treatment for haematologic&#xD;
      measures, G6PD quantification, and drug level assays.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, randomized trial with 72 total participants assigned to one of two treatment&#xD;
      arms. Each arm will have 36 participants comprised of 12 males hemizygous for wildtype G6PD,&#xD;
      12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD with a normal&#xD;
      fluorescent spot test (FST) (G6PD genotype abnormal with G6PD activity ≥40% and ≤80% of&#xD;
      normal). Arm 1a will receive primaquine for 14 days, and Arm 1b will receive chloroquine for&#xD;
      3 days and concomitant primaquine for 14 days. All participants will be healthy volunteers&#xD;
      without severe G6PD deficiency who will be followed for two weeks after completing their&#xD;
      study drug dosing. Pregnant women and those breastfeeding will be excluded. Venous blood&#xD;
      samples will be taken at regular intervals for haematologic measures, G6PD quantification,&#xD;
      and drug level assays. G6PD levels will be measured both by spectrophotometry to provide&#xD;
      whole blood G6PD levels normalized for hemoglobin, as well by flow cytometry to to provide&#xD;
      red blood cell G6PD distributions throughout the treatment and post treatment. Changes in the&#xD;
      G6PD distributions will be modeled, incorporating other critical haematological indicators&#xD;
      collected throughout the study too.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study met study halting rules&#xD;
  </why_stopped>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Actual">October 21, 2018</completion_date>
  <primary_completion_date type="Actual">August 21, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized into one of two arms. 1a will receive primaquine for 14 days, and Arm 1b will receive chloroquine for 3 days and concomitant primaquine for 14 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Haemoglobin</measure>
    <time_frame>28 days after enrollment</time_frame>
    <description>The change in haemoglobin from baseline on exposure to primaquine for P.vivax treatment over treatment course to hemoglobin level at day 28.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in G6PD Concentration</measure>
    <time_frame>28 days after enrollment</time_frame>
    <description>The haemoglobin-related change in G6PD concentration, as determined by spectrometer, over treatment course.&#xD;
Change is determined from baseline to day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significance of CYP2D6</measure>
    <time_frame>28 days after enrollment</time_frame>
    <description>relevance of Dextromethorphan assay results to risk of haemolysis models</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Drug Levels</measure>
    <time_frame>Days 1,2,3,5,7,9,11,14,17,21</time_frame>
    <description>Association of chloroquine and primaquine drug levels at the time of sampling for haematological and G6PD profiles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>28 days after enrollment</time_frame>
    <description>frequency of serious adverse events in women heterozygous for G6PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significance of Reticulocyte Count</measure>
    <time_frame>Days 1,2,3,5,7,9,11,14,17,21</time_frame>
    <description>relevance of reticulocyte count to risk of haemolysis models</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significance of Urobilinogen Levels</measure>
    <time_frame>Days 1,2,3,5,7,9,11,14,17,21</time_frame>
    <description>relevance of urobilinogen tests to risk of haemolysis models</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Malaria, Vivax</condition>
  <condition>G6PD Deficiency</condition>
  <arm_group>
    <arm_group_label>1A: primaquine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1A. Participants in arm 1A will receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1B: chloroquine + primaquine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1B. Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>primaquine</intervention_name>
    <description>Participants receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.</description>
    <arm_group_label>1A: primaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chloroquine + primaquine</intervention_name>
    <description>Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.</description>
    <arm_group_label>1B: chloroquine + primaquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous G6PD test at Shoklo Malaria Research Unit (SMRU) clinic with one of following&#xD;
             results: 1) G6PD homozygous wildtype females (G6PD genotype normal) 2) G6PD&#xD;
             heterozygous females with a normal FST (G6PD genotype abnormal with G6PD activity ≥40%&#xD;
             and ≤80% of normal ) 3) G6PD hemizygous wildtype males (G6PD genotype normal)&#xD;
&#xD;
          -  Willing to participate and sign informed consent form&#xD;
&#xD;
          -  Willing to allow donated samples to be used in future research&#xD;
&#xD;
          -  Aged ≥18 years&#xD;
&#xD;
          -  Ability (in the investigators' opinion) and willing to comply with all study&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All participants:&#xD;
&#xD;
          -  Malaria or other illness&#xD;
&#xD;
          -  Recent history (within 20 days) of anti-malarial treatment&#xD;
&#xD;
          -  History of allergy or adverse reaction to chloroquine or primaquine&#xD;
&#xD;
          -  Blood transfusion in the past 3 months&#xD;
&#xD;
          -  G6PD activity less than 40% normal activity or 3.00 IU/gHb by the quantitative G6PD&#xD;
             spectrophotometric assay&#xD;
&#xD;
          -  Haemoglobin ≤10 g/dL&#xD;
&#xD;
          -  Presence of any condition which in the judgment of the investigator would place the&#xD;
             subject at undue risk or interfere with the results of the study&#xD;
&#xD;
        Female participants only:&#xD;
&#xD;
          -  Pregnancy at the time of screening&#xD;
&#xD;
          -  Breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Nosten, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shoklo Malaria Research Unit (SMRU), Mahidol-Oxford Tropical Medicine Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shoklo Malaria Research Unit (SMRU)</name>
      <address>
        <city>Mae Sot</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <results_first_submitted>May 11, 2021</results_first_submitted>
  <results_first_submitted_qc>October 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 12, 2021</results_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria, Vivax</mesh_term>
    <mesh_term>Glucosephosphate Dehydrogenase Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Primaquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Individual participant data sharing plan will be completed by the time of completion of the study</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT03337152/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>6 participants were enrolled into the trial but had not been randomized at the time of the study halt. Those 6 participants were thus never assigned to a study group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1A: Primaquine</title>
          <description>primaquine: Participants receive primaquine for 14 days at 0.5 mg/Kg.</description>
        </group>
        <group group_id="P2">
          <title>1B: Chloroquine + Primaquine</title>
          <description>chloroquine + primaquine: Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Stopped drug dosing due to study halt</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants randomized to a treatment arm.</population>
      <group_list>
        <group group_id="B1">
          <title>1A: Primaquine</title>
          <description>primaquine: Participants receive primaquine for 14 days at 0.5 mg/Kg.</description>
        </group>
        <group group_id="B2">
          <title>1B: Chloroquine + Primaquine</title>
          <description>chloroquine + primaquine: Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" lower_limit="19" upper_limit="63"/>
                    <measurement group_id="B2" value="38.5" lower_limit="19" upper_limit="64"/>
                    <measurement group_id="B3" value="36" lower_limit="19" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>G6PD Status</title>
          <description>G6PD deficiency status based on genotyping</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Heterozygous Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Homozygous Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hemizygous Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.2" lower_limit="10.1" upper_limit="17.1"/>
                    <measurement group_id="B2" value="12.65" lower_limit="9.6" upper_limit="15.7"/>
                    <measurement group_id="B3" value="12.9" lower_limit="9.6" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>G6PD Concentration</title>
          <description>Based on spectrometer measurement</description>
          <units>IU/g Hb</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.66" lower_limit="2.94" upper_limit="11.08"/>
                    <measurement group_id="B2" value="7.515" lower_limit="3.55" upper_limit="12.66"/>
                    <measurement group_id="B3" value="7.58" lower_limit="2.94" upper_limit="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Haemoglobin</title>
        <description>The change in haemoglobin from baseline on exposure to primaquine for P.vivax treatment over treatment course to hemoglobin level at day 28.</description>
        <time_frame>28 days after enrollment</time_frame>
        <population>Among those with available data at baseline and at least one timepoint after study treatment began.</population>
        <group_list>
          <group group_id="O1">
            <title>1A: Primaquine</title>
            <description>primaquine: Participants receive primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
          <group group_id="O2">
            <title>1B: Chloroquine + Primaquine</title>
            <description>chloroquine + primaquine: Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Haemoglobin</title>
          <description>The change in haemoglobin from baseline on exposure to primaquine for P.vivax treatment over treatment course to hemoglobin level at day 28.</description>
          <population>Among those with available data at baseline and at least one timepoint after study treatment began.</population>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-4.1" upper_limit="0"/>
                    <measurement group_id="O2" value="-1.05" lower_limit="-4.5" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in G6PD Concentration</title>
        <description>The haemoglobin-related change in G6PD concentration, as determined by spectrometer, over treatment course.&#xD;
Change is determined from baseline to day 28</description>
        <time_frame>28 days after enrollment</time_frame>
        <population>Among those with available data at baseline and at least one timepoint after study treatment began.</population>
        <group_list>
          <group group_id="O1">
            <title>1A: Primaquine</title>
            <description>primaquine: Participants receive primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
          <group group_id="O2">
            <title>1B: Chloroquine + Primaquine</title>
            <description>chloroquine + primaquine: Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in G6PD Concentration</title>
          <description>The haemoglobin-related change in G6PD concentration, as determined by spectrometer, over treatment course.&#xD;
Change is determined from baseline to day 28</description>
          <population>Among those with available data at baseline and at least one timepoint after study treatment began.</population>
          <units>IU/g Hb</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" lower_limit="-2.99" upper_limit="-0.34"/>
                    <measurement group_id="O2" value="-1.94" lower_limit="-6.09" upper_limit="-0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Significance of CYP2D6</title>
        <description>relevance of Dextromethorphan assay results to risk of haemolysis models</description>
        <time_frame>28 days after enrollment</time_frame>
        <population>Analysis not possible due to the study termination as the planned risk model could not be developed without sufficient data. Relevance of CYP2D6 results in the model thus unable to be determined.</population>
        <group_list>
          <group group_id="O1">
            <title>1A: Primaquine</title>
            <description>primaquine: Participants receive primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
          <group group_id="O2">
            <title>1B: Chloroquine + Primaquine</title>
            <description>chloroquine + primaquine: Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Significance of CYP2D6</title>
          <description>relevance of Dextromethorphan assay results to risk of haemolysis models</description>
          <population>Analysis not possible due to the study termination as the planned risk model could not be developed without sufficient data. Relevance of CYP2D6 results in the model thus unable to be determined.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association of Drug Levels</title>
        <description>Association of chloroquine and primaquine drug levels at the time of sampling for haematological and G6PD profiles.</description>
        <time_frame>Days 1,2,3,5,7,9,11,14,17,21</time_frame>
        <population>This association was dependent on developing a model which requires completion of the study for an appropriate sample size. The incompletion of the study resulted in it not being possible to generate this model and therefore assess the association of drug levels with hematological and G6PD activity levels</population>
        <group_list>
          <group group_id="O1">
            <title>1A: Primaquine</title>
            <description>primaquine: Participants receive primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
          <group group_id="O2">
            <title>1B: Chloroquine + Primaquine</title>
            <description>chloroquine + primaquine: Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Association of Drug Levels</title>
          <description>Association of chloroquine and primaquine drug levels at the time of sampling for haematological and G6PD profiles.</description>
          <population>This association was dependent on developing a model which requires completion of the study for an appropriate sample size. The incompletion of the study resulted in it not being possible to generate this model and therefore assess the association of drug levels with hematological and G6PD activity levels</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>frequency of serious adverse events in women heterozygous for G6PD</description>
        <time_frame>28 days after enrollment</time_frame>
        <population>All randomized women heterozygous for G6PD.</population>
        <group_list>
          <group group_id="O1">
            <title>1A: Primaquine</title>
            <description>Primaquine: Participants receive primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
          <group group_id="O2">
            <title>1B: Chloroquine + Primaquine</title>
            <description>Chloroquine + primaquine: Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>frequency of serious adverse events in women heterozygous for G6PD</description>
          <population>All randomized women heterozygous for G6PD.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Significance of Reticulocyte Count</title>
        <description>relevance of reticulocyte count to risk of haemolysis models</description>
        <time_frame>Days 1,2,3,5,7,9,11,14,17,21</time_frame>
        <population>The relevance of reticulocyte count was dependent on developing a model which requires completion of the study for an appropriate sample size. The incompletion of the study resulted in it not being possible to generate this model and therefore assess the relevance of reticulocyte count on risk of hemolysis</population>
        <group_list>
          <group group_id="O1">
            <title>1A: Primaquine</title>
            <description>primaquine: Participants receive primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
          <group group_id="O2">
            <title>1B: Chloroquine + Primaquine</title>
            <description>chloroquine + primaquine: Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Significance of Reticulocyte Count</title>
          <description>relevance of reticulocyte count to risk of haemolysis models</description>
          <population>The relevance of reticulocyte count was dependent on developing a model which requires completion of the study for an appropriate sample size. The incompletion of the study resulted in it not being possible to generate this model and therefore assess the relevance of reticulocyte count on risk of hemolysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Significance of Urobilinogen Levels</title>
        <description>relevance of urobilinogen tests to risk of haemolysis models</description>
        <time_frame>Days 1,2,3,5,7,9,11,14,17,21</time_frame>
        <population>The relevance of urobilinogen tests of was dependent on developing a model which requires completion of the study for an appropriate sample size. The incompletion of the study resulted in it not being possible to generate this model and therefore assess the relevance of urobilinogen tests on hemolytic risk models</population>
        <group_list>
          <group group_id="O1">
            <title>1A: Primaquine</title>
            <description>primaquine: Participants receive primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
          <group group_id="O2">
            <title>1B: Chloroquine + Primaquine</title>
            <description>chloroquine + primaquine: Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Significance of Urobilinogen Levels</title>
          <description>relevance of urobilinogen tests to risk of haemolysis models</description>
          <population>The relevance of urobilinogen tests of was dependent on developing a model which requires completion of the study for an appropriate sample size. The incompletion of the study resulted in it not being possible to generate this model and therefore assess the relevance of urobilinogen tests on hemolytic risk models</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days after enrollment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1A: Primaquine</title>
          <description>primaquine: Participants receive primaquine for 14 days at 0.5 mg/Kg.</description>
        </group>
        <group group_id="E2">
          <title>1B: Chloroquine + Primaquine</title>
          <description>chloroquine + primaquine: Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis</sub_title>
                <description>Drug-induced anemia</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Methemoglobinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty sleeping</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Vitamin B1 deficiency</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glucosuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Elevated liver function test</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Common cold</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study met study halting rules and was terminated early. As a result, the full sample size was not enrolled and a complete data set was not available. Thus, the objectives of assessing and developing a G6PD risk model could not be met.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gonzalo Domingo</name_or_title>
      <organization>PATH</organization>
      <phone>206-285-3500</phone>
      <email>gdomingo@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

